Two Alzheimer's drugs that slow the disease will not be made available on the NHS

Breakthrough Alzheimer's drugs, donanemab and lecanemab, are deemed too expensive by the NHS for their limited benefits in slowing the disease progression. National Institute for Health and Care Excellence (NICE) concluded that funding these drugs would not be a good use of taxpayers' money and could necessitate cuts in other services. Despite their potential to delay mild to moderate dementia progression, the cost and marginal benefits of these drugs have led to the decision not to fund them, with the pharmaceutical companies planning to appeal the ruling.